NISH (NITAG Support Hub) 3: Malaria vaccines: Subsaharan countries

Aiman, U., Azad, Z., & Awais, A. R. (2024). Unveiling Malaria's Silent Threat: From Socioeconomic Divides to Religious Influences, A Path to Effective Prevention in India. Journal of vector borne diseases, 10.4103/0972-9062.393978. Advance online publication.            DOI: 10.4103/0972-9062.393978

Takashima, E., Otsuki, H., Morita, M., Ito, D., Nagaoka, H., Yuguchi, T., Hassan, I., & Tsuboi, T. (2024). The Need for Novel Asexual Blood-Stage Malaria Vaccine Candidates for Plasmodium falciparum. Biomolecules, 14(1)    DOI: 10.3390/biom14010100

Datoo, M. S., Dicko, A., Tinto, H., Ouédraogo, J. B., Hamaluba, M., Olotu, A., Beaumont, E., Ramos Lopez, F., Natama, H. M., Weston, S., Chemba, M., Compaore, Y. D., Issiaka, D., Salou, D., Some, A. M., Omenda, S., Lawrie, A., Bejon, P., Rao, H., Chandramohan, D., … R21/Matrix-M Phase 3 Trial Group (2024). Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet (London, England), 403(10426), 533–544. DOI: 10.1016/S0140-6736(23)02511-4

Schmit, N., Topazian, H. M., Natama, H. M., Bellamy, D., Traoré, O., Somé, M. A., Rouamba, T., Tahita, M. C., Bonko, M. D. A., Sourabié, A., Sorgho, H., Stockdale, L., Provstgaard-Morys, S., Aboagye, J., Woods, D., Rapi, K., Datoo, M. S., Lopez, F. R., Charles, G. D., McCain, K., … Winskill, P. (2024). The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study. The Lancet. Infectious diseases, 24(5), 465–475. DOI: 10.1016/S1473-3099(23)00816-2

Chutiyami, M., Saravanakumar, P., Bello, U. M., Salihu, D., Adeleye, K., Kolo, M. A., Dawa, K. K., Hamina, D., Bhandari, P., Sulaiman, S. K., & Sim, J. (2024). Malaria vaccine efficacy, safety, and community perception in Africa: a scoping review of recent empirical studies. Infection, 10.1007/s15010-024-02196-y. Advance online publication.  DOI: 10.1007/s15010-024-02196-y

Li, J., Docile, H. J., Fisher, D., Pronyuk, K., & Zhao, L. (2024). Current Status of Malaria Control and Elimination in Africa: Epidemiology, Diagnosis, Treatment, Progress and Challenges. Journal of epidemiology and global health, 10.1007/s44197-024-00228-2. Advance online publication.  DOI: 10.1007/s44197-024-00228-2

Senkpeil, L., Bhardwaj, J., Little, M. R., Holla, P., Upadhye, A., Fusco, E. M., Swanson, P. A., 2nd, Wiegand, R. E., Macklin, M. D., Bi, K., Flynn, B. J., Yamamoto, A., Gaskin, E. L., Sather, D. N., Oblak, A. L., Simpson, E., Gao, H., Haining, W. N., Yates, K. B., Liu, X., … Tran, T. M. (2024). Innate immune activation restricts priming and protective efficacy of the radiation-attenuated PfSPZ malaria vaccine. JCI insight, 9(11), e167408.   DOI: 10.1172/jci.insight.167408

Tajudeen YA, Oladipo HJ, Yusuff SI, Abimbola SO, Abdulkadir M, Oladunjoye IO, Omotosho AO, Egbewande OM, Shittu HD, Yusuf RO, Ogundipe O, Muili AO, Afolabi AO, Dahesh SMA, Gameil MAM, El-Sherbini MS. (2024). A landscape review of malaria vaccine candidates in the pipeline. Trop Dis Travel Med Vaccines.;10(1):19. doi: 10.1186/s40794-024-00222-3. PMID: 39085983.

Duffy PE, Gorres JP, Healy SA, Fried M. (2024) Malaria vaccines: a new era of prevention and control. Nat Rev Microbiol.  DOI: 10.1038/s41579-024-01065-7 . Epub ahead of print. PMID: 39025972.

Lawal L, Buhari AO, Jaji TA, Alatare AS, Adeyemo AO, Olumoh AO, Yusuff YA, Osborn G, Mogaji AB, Adoto BH, Ibrahim NG, Saliu WO, Abdul-Rahman T. Lingering challenges in malaria elimination efforts in sub-Saharan Africa: Insights and potential solutions. Health Sci Rep. ;7(6):e2122.  DOI: 10.1002/hsr2.2122

Khan, S., Patel, M. P., Patni, A. D., & Cha, S. J. (2024). Targeting Plasmodium Life Cycle with Novel Parasite Ligands as Vaccine Antigens. Vaccines, 12(5), 484.   DOI: 10.3390/vaccines12050484

Hamilton, A., Haghpanah, F., Hasso-Agopsowicz, M., Frost, I., Lin, G., Schueller, E., Klein, E., & Laxminarayan, R. (2023). Modeling of malaria vaccine effectiveness on disease burden and drug resistance in 42 African countries. Communications medicine, 3(1), 144.  DOI: 10.1038/s43856-023-00373-y

Okoth, W. A., Ho, M.-F., Zaman, M., Cooper, E., Som, P., Burgess, M., Walton, M., Nevagi, R. J., Beattie, L., Murphy, D., Stanisic, D. I., & Good, M. F. (2023). A CAF01-adjuvanted whole asexual blood-stage liposomal malaria vaccine induces a CD4⁺ T-cell-dependent strain-transcending protective immunity in rodent models. mBio, 14(6)  DOI: 10.1128/mbio.02547-23

Juraska, M., Early, A. M., Li, L., Schaffner, S. F., Lievens, M., Khorgade, A., Simpkins, B., Hejazi, N. S., Benkeser, D. A., Wang, Q., Mercer, L. D., Adjei, S., Agbenyega, T., Anderson, S., Ansong, D., Bii, D. K., Buabeng, P. B. Y., English, S., Fitzgerald, N., Grimsby, J., … Neafsey, D. E. (2023). Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacy. medRxiv : the preprint server for health sciences. DOI: 10.1101/2023.11.22.23298907

Borkens Y. (2023). Malaria & mRNA Vaccines: A Possible Salvation from One of the Most Relevant Infectious Diseases of the Global South. Acta parasitologica, 68(4), 916–928. DOI: 10.1007/s11686-023-00712-y

Stanisic, D. I., & Good, M. F. (2023). Malaria Vaccines: Progress to Date. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 37(6), 737–756. DOI: 10.1007/s40259-023-00623-4

Rts, S.C.T.P., 2015. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. The Lancet, 386(9988), pp.31-45. doi: 10.1016/S0140-6736(15)60721-8 OR https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626001/ OR https://www.nitag-resource.org/sites/default/files/2022-05/PIIS1473309919303007.pdf OR DOI: 10.1016/S1473-3099(19)30300-7

Hogan, A.B., Winskill, P. and Ghani, A.C., 2020. Estimated impact of RTS, S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: a modelling study. PLoS Medicine, 17(11), p.e1003377.  https://doi.org/10.1371/journal.pmed.1003377